Palvella Therapeutics Common Stock Net 2014-2024 | PVLA

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Palvella Therapeutics common stock net from 2014 to 2024. Common stock net can be defined as the value of common equity ownership.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Palvella Therapeutics common stock net from 2014 to 2024. Common stock net can be defined as the value of common equity ownership.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$139.4B
Bristol Myers Squibb (BMY)	$115.2B
Gilead Sciences (GILD)	$114.5B
Vertex Pharmaceuticals (VRTX)	$104.5B
CSL (CSLLY)	$84.4B
Regeneron Pharmaceuticals (REGN)	$78.6B
GSK (GSK)	$70.4B
Argenex SE (ARGX)	$37.4B
Alnylam Pharmaceuticals (ALNY)	$30.1B
BioNTech SE (BNTX)	$27.6B
Biogen (BIIB)	$21.9B
Illumina (ILMN)	$20.8B
Moderna (MRNA)	$16.2B
Genmab (GMAB)	$13.9B
Incyte (INCY)	$13.4B
BioMarin Pharmaceutical (BMRN)	$12.7B
Insmed (INSM)	$12.5B
Sarepta Therapeutics (SRPT)	$11.9B
Bio-Techne Corp (TECH)	$11.4B
Exact Sciences (EXAS)	$10.5B
Vaxcyte (PCVX)	$10.4B
QIAGEN (QGEN)	$10.2B
Swedish Orphan Biovitrum (BIOVF)	$10.1B
Exelixis (EXEL)	$9.7B
Bio-Rad Laboratories (BIO.B)	$9.1B
Intra-Cellular Therapies (ITCI)	$8.9B
Roivant Sciences (ROIV)	$8.8B
Ascendis Pharma (ASND)	$8.4B
Repligen (RGEN)	$8B
Jazz Pharmaceuticals (JAZZ)	$7.5B